Related Experiment Video

Updated: Jun 1, 2026

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
11:32

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

Pneumocystis carinii pneumonia prophylaxis: current therapies and recommendations

Faith Crozier1

  • 1University of Pennsylvania, Philadelphia, PA, USA. faith_crozier@hotmail.com

Journal of Pediatric Oncology Nursing : Official Journal of the Association of Pediatric Oncology Nurses
|June 4, 2011
PubMed

Insights

Pneumocystis pneumonia (PCP) prophylaxis is crucial for immunocompromised children. While Bactrim is most effective, alternative drugs are being studied for those with allergies or side effects.

Area of Science:

  • Pediatric Oncology
  • Infectious Diseases
  • Pharmacology

Background:

  • Pneumocystis pneumonia (PCP) poses a life-threatening risk to pediatric patients undergoing chemotherapy and immunosuppressive therapy.
  • Current guidelines for PCP prophylaxis in pediatric oncology are lacking.
  • High-dose steroids contribute to increased susceptibility.

Purpose of the Study:

  • To review current practices and ongoing research in Pneumocystis pneumonia prophylaxis for pediatric oncology patients.
  • To highlight the efficacy and challenges associated with different prophylactic agents.
  • To emphasize the importance of patient and family education on prophylaxis compliance.

Main Methods:

  • Review of current clinical practices for PCP prophylaxis in pediatric oncology.
  • Analysis of ongoing studies evaluating drug efficacy, side effects, administration, and compliance.
  • Identification of commonly prescribed prophylactic agents: Bactrim, pentamidine, dapsone, and atovaquone.

Main Results:

  • Bactrim (trimethoprim-sulfamethoxazole) is considered superior for PCP prevention.
  • Alternative agents are being investigated for patients intolerant to Bactrim due to allergies or adverse effects.
  • No universal guidelines currently exist for PCP prophylaxis in this vulnerable population.

Conclusions:

  • PCP prophylaxis is essential for pediatric oncology patients on immunosuppressive medications.
  • Ongoing research aims to optimize prophylaxis strategies, including exploring alternatives to Bactrim.
  • Healthcare providers must prioritize educating patients and families on the importance of adherence to PCP prophylaxis regimens.

Related Concept Videos

Pneumonia V: Nursing management and Prevention01:30

Pneumonia V: Nursing management and Prevention

Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Cryptococcal Meningitis01:27

Cryptococcal Meningitis

Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...
Pneumonia I: Introduction01:29

Pneumonia I: Introduction

Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following: